• Almirall outlined new clinical and real-world evidence for lebrikizumab in atopic dermatitis, with results presented at EADV 2026.
• Data showed consistent symptom control across body regions, including face and neck involvement, supporting broader use in high-impact disease.
• A late-breaking ADlong update to be presented at EADV reported sustained improvements in skin signs and itch with up to five years’ treatment.
• New POSITIVE two-year findings presented at EADV indicated tildrakizumab improved overall well-being and quality of life beyond skin clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300100BIZWIRE_USPR_____20260929_BW500868) on September 30, 2026, and is solely responsible for the information contained therein.